Overview of current policy for rare disease in China
2018 was regarded as a milestone of rare disease management in China as, for the first time after decades of negligence in this area, China published the First List of Rare Diseases (FLRDs). This was a key step in improving and standardising the regulatory system of rare disease management, orphan drug development, and review and approval.
In this FLRDs, 121 diseases were included and officially defined as rare diseases. Since then, a series of regulations and policies have been released and implemented to support the development of rare disease treatment and management.
Several key trends on the current policy and market dynamics for rare disease in China are outlined in this paper. With strong expertise and deep understanding of the rare disease field in China, Deallus is well-positioned to support Pharma to fully understand the current landscape and maximise success in the market.
Download to read more.
You may also be interested in…
Overview of current policy for rare disease in China
For the first time after decades of negligence in this area, China published the First List of Rare Diseases (FLRDs). This was a key step in improving and standardising the regulatory system of rare disease management, orphan drug development, and review and approval.
HIV/AIDS
Human immunodeficiency virus (HIV) is the virus that is responsible for Acquired Immune Deficiency Syndrome (AIDS). HIV continues to be a major global public health issue having claimed the lives of 36.3 million people so far, according to World Health Organization (WHO).
Deallus Workshops: providing competitive advantage through Competitive Simulation
Competitive Simulation, also known as Competitive Strategy or ‘Wargaming’ workshops, account for roughly 85% of the workshops that Deallus run. We have developed a detailed and comprehensive workshop playbook that ensures our teams are well-prepared and well-versed with a set of tools ready to run your sessions.
Post-ASCO 2022: Summary of key breast cancer highlights
With the conclusion of another ASCO, we were presented with exciting new breakthrough data of Antibody Drug Conjugates in breast cancer. Enhertu (trastuzumab deruxtecan) demonstrated significant benefit in the treatment of a new subtype of breast cancer, HR+/ /HER2-low.